Pharmacokinetics of Lorlatinib After Single and Multiple Dosing in Patients with Anaplastic Lymphoma Kinase (ALK)-Positive Non-Small Cell Lung Cancer: Results from a Global Phase I/II Study.

Joseph ChenMelissa T O'GormanLee P JamesKaren J KlamerusGanesh MugunduYazdi K Pithavala

Published in: Clinical pharmacokinetics (2021)

Lorlatinib is highly brain penetrant and exhibits autoinduction after multiple dosing. There appears to be no inherent differences in lorlatinib PK between healthy subjects and cancer patients, or between Asian and non-Asian patients. ClinicalTrials.gov NCT01970865.

Keyphrases

end stage renal disease
ejection fraction
newly diagnosed
peritoneal dialysis
prognostic factors
white matter
resting state
patient reported outcomes
tyrosine kinase
protein kinase
brain injury
cerebral ischemia
subarachnoid hemorrhage